Meta-analysis: high serum adiponectin tied to mortality risk

  • Scarale MG & al.
  • J Clin Endocrinol Metab
  • 1 Nov 2018

  • curated by Brian Richardson, PhD
  • Clinical Essentials
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • A systematic review and meta-analysis suggest that high serum levels of adiponectin are associated with an increased mortality rate, which is partly modulated by natriuretic peptides.

Why this matters

  • Serum adiponectin was thought to have a beneficial role in the treatment of cardiovascular disease, but recent studies and this meta-analysis suggest a surprising link between high adiponectin levels and mortality.

Key results

  • High serum adiponectin was associated with increased all-cause mortality (HR, 1.24; P<.0001 and cardiovascular mortality>
  • In studies adjusting for natriuretic peptides, the association between adiponectin and mortality was attenuated (HR, 1.13 [P=.0003] for all-cause mortality; HR, 1.15 [P=.001] for cardiovascular mortality).

Study design

  • 55 studies including 61,676 subjects and 28 studies including 43,979 subjects reported associations between adiponectin and all-cause and cardiovascular mortality, respectively, and were subjected to meta-analysis.
  • Funding: Italian Ministry of Health; Italian Ministry of University and Scientific Research; Società Italiana di Diabetologia-Fondazione Diabete Ricerca.

Limitations

  • Analysis assumed a linear association between adiponectin and morality.

Please confirm your acceptance

To gain full access to GPnotebook please confirm:

By submitting here you confirm that you have accepted Terms of Use and Privacy Policy of GPnotebook.

Submit